1-4 of 4
Winfried F. Pickl, M.D.
Close
Sort by
Journal Articles

Dasatinib Inhibits the Growth of Neoplastic Human Eosinophils (EOL-1) through Targeting of FIP1L1-PDGFRα.

Christian Baumgartner, MD, Karoline V. Gleixner, M.D., Alexander Gruze, Puchit Samorapoompichit, M.D., Harald Esterbauer, M.D, Winfried F. Pickl, M.D, Christian Sillaber, M.D., Peter Valent, M.D.
Journal: Blood
Blood (2007) 110 (11): 3559.
https://doi.org/10.1182/blood.V110.11.3559.3559
Published: 2007
Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.

Veronika Ferenc, MD, Karoline V. Gleixner, M.D., Alexander Gruze, M.D., Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.
Journal: Blood
Blood (2007) 110 (11): 3554.
https://doi.org/10.1182/blood.V110.11.3554.3554
Published: 2007
Journal Articles

Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib

Karoline V. Gleixner, MD, Matthias Mayerhofer, M.D., Uwe Rix, Ph.D., Gregor Hoermann, Alexander Gruze, Maria-Theresa Krauth, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Giulio Superti-Furga, Ph.D., Peter Valent, M.D.
Journal: Blood
Blood (2007) 110 (11): 1541.
https://doi.org/10.1182/blood.V110.11.1541.1541
Published: 2007
Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition.

Karoline V. Gleixner, MD, Veronika Ferenc, M.D., Alexander Gruze, Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.
Journal: Blood
Blood (2007) 110 (11): 1046.
https://doi.org/10.1182/blood.V110.11.1046.1046
Published: 2007